Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 2/20 | 0.40 |
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC2 known ✓ | Q92769 | 2/20 | 0.40 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 2/20 | 0.40 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.36 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.36 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.36 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.36 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.36 |
| ▸ | SLC6A1 known ✓ | P30531 | 1/20 | 0.36 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.36 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.36 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.36 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.36 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.36 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.36 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.36 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL61373 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Hydrochloric Acid SCHEMBL38657781 | 1.00 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Hydrochloric Acid SCHEMBL559051 | 0.97 | LMNA (0.47) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| SCHEMBL28981504 | 0.97 | LMNA (0.53) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| SCHEMBL40381 | 0.97 | LMNA (0.53) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| SCHEMBL2121788 | 0.93 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Phosphine SCHEMBL1906956 | 0.93 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| SCHEMBL20872325 | 0.93 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Water SCHEMBL4632803 | 0.93 | LMNA (0.50) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Hypochlorous Acid SCHEMBL3408792 | 0.90 | LMNA (0.47) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4286387-A2 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11793885-B2 | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders | IMMUNOGEN, INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-3778602-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-4163284-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| EP-3778601-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778602-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3325482-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-06-24 | — | — | EP | disclosed |
| EP-3189056-B1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3653628-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | ImmunoGen, Inc. (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3325485-B1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10392407-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190010169-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-01-10 | — | — | US | disclosed |
| US-20180346488-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF | IMMUNOGEN, INC. | 2018-12-06 | — | — | US | disclosed |
| WO-2018161049-A1 | COMPOSITIONS AND METHODS FOR INDUCING HIV-1 ANTIBODIES | DUKE UNIVERSITY (US) | 2018-09-07 | — | — | WO | disclosed |
| US-20120004179-A1 | MEANS AND METHODS FOR MANUFACTURING HIGHLY PURE NEUROTOXIN | MERZ PHARMA GMBH & CO. KGAA (DE) | 2012-01-05 | — | — | US | disclosed |
| WO-2011048044-A1 | SYSTEM FOR DETERMINING UNPROCESSED AND PARTIALLY PROCESSED NEUROTOXIN TYPE A | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11116845-B2 | Cytotoxic benzodiazepine derivatives | GABRA6, GABBR1, GABRA5 | HDAC3 535/4885HDAC1 1801/4885HDAC2 1862/4885 |
| US-20230233697-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA6, GABBR1, GABRA5 | HDAC3 535/4885HDAC1 1801/4885HDAC2 1862/4885 |
| US-20180346488-A1 | CYTOTOXIC BENZODIAZEPINE DERIVATIVES AND CONJUGATES THEREOF | GABRA5, GABRA1, GABRA6 | HDAC3 369/4885HDAC1 1366/4885HDAC2 1396/4885 |
| US-10392407-B2 | Methods of preparing cytotoxic benzodiazepine derivatives | GABRA3, GABRA5, GABRB3 | HDAC3 577/4885HDAC1 3117/4885HDAC2 1641/4885 |
| US-20230257400-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | HDAC3 577/4885HDAC1 3117/4885HDAC2 1641/4885 |
| US-20190010169-A1 | METHODS OF PREPARING CYTOTOXIC BENZODIAZEPINE DERIVATIVES | GABRA3, GABRA5, GABRB3 | HDAC3 577/4885HDAC1 3117/4885HDAC2 1641/4885 |
| US-11793885-B2 | Substituted benzo[5,6][1,4]diazepino[1,2-a]indoles for the treatment of proliferative disorders | MKI67, GABBR1, GABBR2 | HDAC3 690/4885HDAC1 1371/4885HDAC2 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.